Therini Bio Inc.

4 trials 1 recruiting Commercial sponsor Merged from 2 name variants

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

1 Recruiting

3 Completed trials

5 Countries active

1 Unique IMPs

100% Results reported

Phase II

Phase I

Phase I (Other)

Phase II: 1 Phase I: 1 Phase I (Other): 2

Oversight events:

1 temporary halt across 1 trial

View oversight register →

100%

3 of 3 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Top IMPs

HUMAN IGG1 BISPECIFIC MONOCLONAL ANTIBODY AGAINST KALLIKREIN-5 AND KALLIKREIN-7 1

All trials

4 total

A Study to Evaluate the Effect of TRIV-509 on Skin Barrier Function in Patients with Atopic Dermatitis. Recruiting

2025-522635-34-00 Phase I (Other) 1 country
A study to investigate the efficacy and safety of TRIV-509 compared with placebo in adults with moderate to severe atopic dermatitis Ended

2025-522113-35-00 Phase II 4 countries HUMAN IGG1 BISPECIFIC MONOCLONAL ANTIBODY AGAINST KALLIKREIN-5 AND KALLIKREIN-7
A Double-Blind, Randomized, Placebo-Controlled, Phase 1b Study to Assess the Safety, Tolerability, and Pharmacokinetics of Multiple Ascendin… Ended

2024-519899-72-00 Phase I (Other) 1 country
A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PHASE I STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SINGLE ANDMULTIPLE… Ended

2024-517955-10-00 Phase I 1 country

Showing 1–4 of 4 trials

← All sponsors A–Z